Federal Register / Vol. 72, No. 109 / Thursday, June 7, 2007 / Notices 31591 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Adaku Nwachukwu, J.D., 

Technology Licensing Specialist, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435–

5560; Facsimile: (301) 402–0220; E-mail: 

madua@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

technology relates to an effective way to 

monitor food quality and freshness in 

real time. The major factor for food 

spoilage is the release of volatile bases 

due to the action of enzymes contained 

within the food or produced by 

microorganisms, such as bacteria, yeasts 

and molds growing in the food. The rate 

of release of such bases depends on 

food’s storage history. In this 

technology, a reactive dye locked in a 

water-repellent material reacts with the 

bases released during food 

decomposition, and changes color. Thus 

a rapid and informed decision can be 

made about quality of food and its shelf 

life under the storage conditions used. 

Since the detection is based on 

biological processes that are the root 

cause for food spoilage, these indicators 

are much more reliable. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: May 21, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–10963 Filed 6–6–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substances Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMSHA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMSHA Reports 

Clearance Officer on (240) 276–1243. 

Project: Community Mental Health 

Services Block Grant Application 

Guidance and Instruction, FY 2008–

2010 (OMB No. 0930–0168)—Revisions 

Sections 1911 through 1920 of the 

Public Health Service Act (42 U.S.C. 

300x through 300x–9) provide for 

annual allotments to assist States to 

establish or expand an organized, 

community-based system of care for 

adults with serious mental illnesses and 

children with serious emotional 

disturbances. Under these provision of 

the law, States may receive allotments 

only after an application is submitted 

and approved by the Secretary of the 

Department of Health and Human 

Services. 

For the FY 2008–2010 Community 

Mental Health Services Block Grant 

application cycle, SAMSHA will 

provide States guidance and 

instructions to guide development of 

comprehensive State applications/plans 

and implementation reports. Proposed 

revisions to the guidance include: 

(1) The integration of mental health 

transformation as a guiding principle in 

the development of State mental health 

plans. State plans for FY 2008–2010 will 

describe State mental health 

transformation efforts and activities 

within the context of the five (5) 

legislative criteria, identify mental 

health transformation activities funded 

by the MHBG and other State funding 

sources, identify activities of the State 

mental health planning council that 

contribute to and support State 

transformation efforts, include one State 

transformation performance indicator in 

the plan, and include a description of 

the services provided to older adults 

under criterion 4 of the State’s plan. 

(2) The introduction of the Web Block 

Grant Application System (WebBGAS). 

WebBGAS enables States to submit 

applications/plans, and implementation 

reports electronically thus reducing the 

burden of paperwork required for 

submission, revision, and reporting 

purposes. In FY 2008, all States and 

Territories will be encouraged to submit 

State plans using WebBGAS. Other 

advantages to using WebBGAS include: 

• Eliminating redundancy in data 

entry by pre-populating the States’

previous year data in the current year’s 

plans and implementation reports. 

• Standardizing Mental Health Block 

Grant data for reporting and quantitative 

analysis. 

• Allowing the States’ mental health 

planning councils to have access to state 

plans and implementation reports 

throughout the FY as a means to enable 

councils to meet their Federal mandate 

of reviewing the plans and providing 

recommendations to the State. 

• Adhering to the Federal 

Government’s e-governments and egrants initiatives, where applicable. 

(3) A requirement for States to report 

nine CMHS National Outcome Measures 

(NOMS) for mental health. All nine 

measures are derived from tables in the 

Uniform Reporting System (URS) which 

was developed in collaboration with the 

States. Four (4) of the nine measures 

were established, in concert with OMB 

PART, to support the long-term goals of 

the Mental Health Block Grant program 

and SAMSHA’s Government Results 

and Performance Act (GPRA) measures. 

The nine CMHS measures are: 

• Increased access to services 

• Reduced utilization of psychiatric 

inpatient beds for 30 and 180 days 

• Number of evidenced-based 

practices and number of persons served 

in these programs 

• Client perception of care 

• Increased/retained employment or 

returned to/stayed in school 

• Decreased criminal justice 

involvement 

• Increased stability in housing 

• Increased social supports and social 

connectedness, and 

• Improved level of functioning. 

Two of the NOMS, Increased Social 

Supports and Social Connectedness, 

and Improved Functioning, are 

currently under development at 

SAMSHA. States that are unable to 

report data on these or other indicators 

will be required to describe their current 

reporting capacity and efforts underway 

to make collection of the data possible. 

(4) Revisions to tables in the Uniform 

Reporting System (URS). Since FY 2001, 

States have reported annual data on the 

public mental health system to the 

MHBG Program through 21 tables in the 

URS. For the past three years, CMHS 

worked collaboratively with States, 

using the Data Infrastructure Grant (DIG) 

process, to refine the data and make 


rwilkins on PROD1PC63 with NOTICES
31592 Federal Register / Vol. 72, No. 109 / Thursday, June 7, 2007 / Notices 

reporting more meaningful to both 

States and CMHS. This effort resulted in 

a list of revisions to the basic and 

development tables in the FY 2005–

2007 MHBG guidance. The revisions to 

the URS tables are described below: 

REVISIONS TO TABLES IN THE UNIFORM REPORTING SYSTEM

Table description 

Table No. Table name Change Proposed change 

Table 1 ................... Profile of State Population by Diagnosis ............. No Change ............

Table 2 ................... Total Unduplicated Served by Age, Gender & 

Race.

Minor ..................... Combine Age 0–3 with Age 4–12. 

Table 3 ................... Total Served by Setting, by Age & Gender ......... No Change ............

Table 4 ................... Employment .......................................................... Minor ..................... Add Optional Table 4a. Reporting of Employment Status by 5 Diagnostic Groupings. 

Table 5 ................... Medicaid Status .................................................... No Change ............

Table 6 ................... Profile of Client Flow and Turnover ..................... Minor ..................... Add Column for Length of Stay for clients in facility more than 1 year. 

Table 7 ................... State MH Expenditures and Revenues ................ No Change ............

Table 8 ................... Profile of Community MHBG Expenditures .......... No Change ............

Table 9 ................... Public Mental Health Service System Inventory 

List (Deleted in 2005).

Major ..................... New table added, ‘‘Social Connectedness and 

Improved Functioning’’ for SAMHSA’s newest 

NOMS. 

Table 10 ................. Profile of Agencies receiving MHBG Funds ........ No Change ............

Table 11 ................. Consumer Evaluation of Care* ............................ Minor ..................... Add revisions to table and questions to clarify 

the survey instrument and methodology used 

to collect data for this domain if the recommended survey was not used. 

Table 12 ................. State Mental Health Agency Profile ..................... No Change ............

Table 13 ................. Untreated Prevalence of Mental Illness ............... No Change ............ Continue as developmental until refined by DIG 

Workgroup. 

Table 14 ................. Adults with SMI & SED served by Age, gender, 

Race, & Ethnicity.

Minor ..................... Combine Age 0–3 with Age 4–12. 

Table 15 ................. Living Situation Profile .......................................... No Change ............

Table 16 ................. EBPs ..................................................................... Minor ..................... Add two questions at the end of each EBP: 

(1) Did the State use the SAMHSA Toolkit 

to guide implementation? 

(2) Has staff been specifically trained to implement the EBP? 

Table 17 ................. EBPs ..................................................................... Minor ..................... Add two questions at the end of each EBP: 

(1) Did the State use the SAMHSA Toolkit 

to guide implementation? 

(2) Has staff been specifically trained to implement the EBP? 

Table 18 ................. Use of New Generation Atypical Antipsychotics .. No Change ............

Table 19 ................. Outcomes: Criminal Justice & School Attendance Minor ..................... Add new questions for two CMHS NOMS: Arrests, and School Attendance. 

Table 20 ................. 30 and 180 day state hospital readmissions ....... Minor ..................... Combine Age 0–3 with Age 4–12. 

Table 21 ................. 30 and 180 day readmission to any psych bed ... Minor ..................... Combine Age 0–3 with Age 4–12. 

The future of the SAMHSA/CMHS 

State mental data reporting program 

continues to evolve with a related plan 

to implement a State Client level 

Initiative project with a few States to 

test the feasibility of implementing 

client level reporting in the States. 

Activities of this pilot in the next three 

years will include: (1) Identifying and 

documenting the States’ most promising 

approaches to the collection of clientlevel data; (2) developing 

recommendations for expanding clientlevel data collection systems to 

incorporate the NOMs; and (3) pilot 

testing the most promising approaches 

with other interested States to 

determine their feasibility. SAMHSA 

expects that the results of this effort will 

improve the ability of States to report 

unduplicated client-level outcomes 

comparing Time 2 to Time 1. These data 

are expected to support the CMHS Block 

Grant in future PART reviews. 

The following table summarizes the 

annual burden for the revised 

application. 

Application Number of 

respondents 

Responses/ 

respondent 

Burden 

response 

(hrs) 

Total burden 

hours 

Plan: 

1 year ........................................................................................................ 44 1 180 7,920 

2 year ........................................................................................................ 6 1 150 900 

3 year ........................................................................................................ 9 1 110 990 

Implementation Report .................................................................................... 59 1 75 4,425 

URS Tables ..................................................................................................... 59 1 40 2,360 

Total .......................................................................................................... 59 ........................ ........................ 16,595 


rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 109 / Thursday, June 7, 2007 / Notices 31593 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent by July 9, 2007 to: SAMHSA 

Desk Officer, Human Resources and 

Housing Branch, Office of Management 

and Budget, New Executive Office 

Building, Room 10235, Washington, DC 

20503; due to potential delays in OMB’s 

receipt and processing of mail sent 

through the U.S. Postal Service, 

respondents are encouraged to submit 

comments by fax to: 202–395–6974. 

Dated: June 1, 2007. 

Elaine Parry, 

Acting Director, Office of Program Services. 

[FR Doc. 07–2851 Filed 6–6–07; 8:45 am] 

BILLING CODE 4162–20–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov 

and http://www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; 240–276–2600 (voice), 240–276–

2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290–

1150. 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400. 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800–

445–6917. 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913, 239–561–8200/800–735–

5416. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671–

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

Dynacare Kasper Medical Laboratories*, 

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702/800–661–9876. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662–

236–2609. 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519–

679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823, (Formerly: 

Laboratory Specialists, Inc.). 

Kroll Laboratory Specialists, Inc., 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 13112 Evening Creek Drive, 

Suite 100, San Diego, CA 92128, 858–

668–3710/800–882–7272, (Formerly: 

Poisonlab, Inc.). 

Laboratory Corporation of America 

Holdings, 550 17th Ave., Suite 300, 

Seattle, WA 98122, 206–923–7020/ 

800–898–0180 (Formerly: DrugProof, 

Division of Dynacare/Laboratory of 

Pathology, LLC; Laboratory of 

Pathology of Seattle, Inc.; DrugProof, 

Division of Laboratory of Pathology of 

Seattle, Inc.). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339. (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 


rwilkins on PROD1PC63 with NOTICES